6,252 trials (keyword fallback)
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Phase I - Dose-Limiting Toxicity — 0; 0 dose-limiting toxicities
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-small Cell Lung Cancer
Primary: Part 1: Overall Survival (OS) — 15.9; 20.1; 13.9 months — p=0.1782
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Basal Cell Carcinoma · Squamous Cell Carcinoma in Situ
Primary: Tumor Clearance — 2; 2; 5 Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months
Non-Small Cell Lung Cancer · Malignant Melanoma · Head and Neck Squamous Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg
Head and Neck Cancer
Primary: Percent of Participants With Disease-Free Survival (DFS) at 3 Years — 69.5 Percent